With new ac­qui­si­tion, Bo­ra to ven­ture in­to bi­o­log­ics

Last week, Tai­wan-based CD­MO Bo­ra Phar­ma­ceu­ti­cals an­nounced that it ac­quired Eden Bi­o­log­ics. Now, it says that pur­chase has helped es­tab­lished Bo­ra Bi­o­log­ics, ex­pand­ing in­to the bio­phar­ma­ceu­ti­cal mar­ket.

The ac­qui­si­tion of the com­pa­ny’s as­sets, which are lo­cat­ed in the Hsinchu Bio­med­ical Sci­ence Park in Tai­wan, is help­ing Bo­ra build its pres­ence in the bio­phar­ma world by ex­pand­ing pro­duc­tion ca­pac­i­ty of cell lines for the pro­duc­tion of pro­tein drugs. It will al­so im­prove the qual­i­ty con­trol and in­spec­tion spec­i­fi­ca­tions, as well as cell bank gen­er­a­tion. The fa­cil­i­ty has four 500-liter biore­ac­tors that have been ap­proved by Eu­ro­pean and Tai­wanese reg­u­la­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER